Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C.

Journal Article (Journal Article)

SOURCE CITATION: Hao Q, Aertgeerts B, Guyatt G, et al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. BMJ. 2022;377:e069066. 35508320.

Full Text

Duke Authors

Cited Authors

  • Kelsey, MD; Newby, LK

Published Date

  • August 2022

Published In

Volume / Issue

  • 175 / 8

Start / End Page

  • JC86 -

PubMed ID

  • 35914252

Electronic International Standard Serial Number (EISSN)

  • 1539-3704

Digital Object Identifier (DOI)

  • 10.7326/J22-0060

Language

  • eng

Conference Location

  • United States